These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23644530)

  • 1. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
    Carbonell WS; DeLay M; Jahangiri A; Park CC; Aghi MK
    Cancer Res; 2013 May; 73(10):3145-54. PubMed ID: 23644530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy.
    DeLay M; Jahangiri A; Carbonell WS; Hu YL; Tsao S; Tom MW; Paquette J; Tokuyasu TA; Aghi MK
    Clin Cancer Res; 2012 May; 18(10):2930-42. PubMed ID: 22472177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
    Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
    Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
    Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
    Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma.
    Hu YL; DeLay M; Jahangiri A; Molinaro AM; Rose SD; Carbonell WS; Aghi MK
    Cancer Res; 2012 Apr; 72(7):1773-83. PubMed ID: 22447568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β1 integrin: Critical path to antiangiogenic therapy resistance and beyond.
    Jahangiri A; Aghi MK; Carbonell WS
    Cancer Res; 2014 Jan; 74(1):3-7. PubMed ID: 24327727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer.
    Jahangiri A; Nguyen A; Chandra A; Sidorov MK; Yagnik G; Rick J; Han SW; Chen W; Flanigan PM; Schneidman-Duhovny D; Mascharak S; De Lay M; Imber B; Park CC; Matsumoto K; Lu K; Bergers G; Sali A; Weiss WA; Aghi MK
    Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8685-E8694. PubMed ID: 28973887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
    Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
    Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
    Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
    Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
    Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for glioblastoma: current indications, surgical implications, and future directions.
    Castro BA; Aghi MK
    Neurosurg Focus; 2014 Dec; 37(6):E9. PubMed ID: 25581938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
    Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
    JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma.
    Nigim F; Kiyokawa J; Gurtner A; Kawamura Y; Hua L; Kasper EM; Brastianos PK; Cahill DP; Rabkin SD; Martuza RL; Carbonell WS; Wakimoto H
    Target Oncol; 2019 Aug; 14(4):479-489. PubMed ID: 31301014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophils promote the malignant glioma phenotype through S100A4.
    Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
    Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
    Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
    Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.